IE48717B1 - A pharmaceutical preparation comprising a cardiac glycoside in combination with a polymer,and a process for preparation thereof - Google Patents

A pharmaceutical preparation comprising a cardiac glycoside in combination with a polymer,and a process for preparation thereof

Info

Publication number: IE48717B1
Authority: IE; Ireland
Prior art keywords: preparation; cardiac glycoside; polymer; layer; cardiac
Prior art date: 1978-12-22

Application number

IE245579A

Other languages

English (en)

Other versions

IE792455L (en

Original Assignee

Haessle Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-12-22

Filing date

1979-12-18

Publication date

1985-05-01

1978-12-22 Priority claimed from SE7813245A external-priority patent/SE426548B/sv

1979-12-18 Application filed by Haessle Ab filed Critical Haessle Ab

1980-06-22 Publication of IE792455L publication Critical patent/IE792455L/xx

1985-05-01 Publication of IE48717B1 publication Critical patent/IE48717B1/en

Links

229940097217 cardiac glycoside Drugs 0.000 title claims abstract description 27
239000002368 cardiac glycoside Substances 0.000 title claims abstract description 27
229930002534 steroid glycoside Natural products 0.000 title claims abstract description 27
238000002360 preparation method Methods 0.000 title claims abstract description 24
229920000642 polymer Polymers 0.000 title claims abstract description 20
LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 title claims abstract description 18
239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 16
238000000034 method Methods 0.000 title claims abstract description 15
239000000463 material Substances 0.000 claims abstract description 8
238000005507 spraying Methods 0.000 claims abstract description 7
239000000203 mixture Substances 0.000 claims description 7
125000000129 anionic group Chemical group 0.000 claims description 5
239000012530 fluid Substances 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 4
239000007787 solid Substances 0.000 claims description 3
239000002253 acid Substances 0.000 abstract description 4
210000002784 stomach Anatomy 0.000 abstract description 4
230000000747 cardiac effect Effects 0.000 abstract description 3
239000011248 coating agent Substances 0.000 abstract description 3
238000000576 coating method Methods 0.000 abstract description 3
239000002245 particle Substances 0.000 abstract 1
239000011162 core material Substances 0.000 description 13
LTMHDMANZUZIPE-UHFFFAOYSA-N 3-[3-[5-[5-(4,5-dihydroxy-6-methyloxan-2-yl)oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2h-furan-5-one Chemical compound C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 9
150000008143 steroidal glycosides Chemical class 0.000 description 9
239000004480 active ingredient Substances 0.000 description 8
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 7
229960005156 digoxin Drugs 0.000 description 7
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 7
150000001875 compounds Chemical class 0.000 description 6
229940082657 digitalis glycosides Drugs 0.000 description 5
125000005498 phthalate group Chemical group 0.000 description 5
210000004051 gastric juice Anatomy 0.000 description 4
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
235000011389 fruit/vegetable juice Nutrition 0.000 description 3
230000000968 intestinal effect Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
238000013268 sustained release Methods 0.000 description 3
QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 2
208000020446 Cardiac disease Diseases 0.000 description 2
WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 2
229920003137 Eudragit® S polymer Polymers 0.000 description 2
JAYAGJDXJIDEKI-PTGWOZRBSA-N Lanatoside C Chemical compound O([C@H]1[C@@H](OC(C)=O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@@H]1C[C@@H]2[C@]([C@@H]3[C@H]([C@]4(CC[C@@H]([C@@]4(C)[C@H](O)C3)C=3COC(=O)C=3)O)CC2)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JAYAGJDXJIDEKI-PTGWOZRBSA-N 0.000 description 2
JAYAGJDXJIDEKI-UHFFFAOYSA-N Lanatoside C Natural products CC1OC(OC2CC3C(C4C(C5(CCC(C5(C)C(O)C4)C=4COC(=O)C=4)O)CC3)(C)CC2)CC(O)C1OC(OC1C)CC(O)C1OC(OC1C)CC(OC(C)=O)C1OC1OC(CO)C(O)C(O)C1O JAYAGJDXJIDEKI-UHFFFAOYSA-N 0.000 description 2
MYEJFUXQJGHEQK-ALRJYLEOSA-N Proscillaridin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C=C2CC[C@H]3[C@@]4(O)CC[C@H](C5=COC(=O)C=C5)[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1 MYEJFUXQJGHEQK-ALRJYLEOSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
206010003119 arrhythmia Diseases 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000007931 coated granule Substances 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
229960000648 digitoxin Drugs 0.000 description 2
WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 2
239000002702 enteric coating Substances 0.000 description 2
238000009505 enteric coating Methods 0.000 description 2
208000019622 heart disease Diseases 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
229960002614 lanatoside c Drugs 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
229920002689 polyvinyl acetate Polymers 0.000 description 2
239000011118 polyvinyl acetate Substances 0.000 description 2
229930190098 proscillaridin Natural products 0.000 description 2
229960003584 proscillaridin Drugs 0.000 description 2
MYEJFUXQJGHEQK-UHFFFAOYSA-N proscillaridin A Natural products OC1C(O)C(O)C(C)OC1OC1C=C2CCC3C4(O)CCC(C5=COC(=O)C=C5)C4(C)CCC3C2(C)CC1 MYEJFUXQJGHEQK-UHFFFAOYSA-N 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000000126 substance Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
229920003136 Eudragit® L polymer Polymers 0.000 description 1
229920003141 Eudragit® S 100 Polymers 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
JDYLJSDIEBHXPO-ALNZGLKXSA-N [(2r,3r,4s,6r)-3-[(2s,4s,5r,6r)-4-acetyloxy-5-[(2s,4s,5r,6r)-4,5-diacetyloxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-6-[[(3s,5r,8r,9s,10s,13r,14s,16s,17r)-16-acetyloxy-14-hydroxy-10,13-dimethyl-17-(5-oxo-2h-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17 Chemical compound O([C@H]1[C@@H](OC(C)=O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](OC(C)=O)C[C@@H](O[C@@H]1C)O[C@@H]1C[C@@H]2[C@]([C@@H]3[C@H]([C@]4(C[C@@H]([C@@H]([C@@]4(C)CC3)C=3COC(=O)C=3)OC(C)=O)O)CC2)(C)CC1)[C@H]1C[C@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](C)O1 JDYLJSDIEBHXPO-ALNZGLKXSA-N 0.000 description 1
229940081735 acetylcellulose Drugs 0.000 description 1
229960003304 acetyldigoxin Drugs 0.000 description 1
HWKJSYYYURVNQU-DXJNJSHLSA-N acetyldigoxin Chemical compound C1[C@H](OC(C)=O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O HWKJSYYYURVNQU-DXJNJSHLSA-N 0.000 description 1
239000013543 active substance Substances 0.000 description 1
ACLJAFRNPZVVIW-ADFGDECNSA-N actodigin Chemical compound O([C@@H]1C[C@H]2CC[C@@H]3[C@@H]([C@]2(CC1)C)CC[C@]1([C@]3(O)CC[C@@H]1C=1C(OCC=1)=O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ACLJAFRNPZVVIW-ADFGDECNSA-N 0.000 description 1
229950004735 actodigin Drugs 0.000 description 1
239000000654 additive Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
MGVYFNHJWXJYBE-UHFFFAOYSA-N alpha-Acetyl-digoxin Natural products CC1OC(CC(O)C1O)OC2C(O)CC(OC3C(C)OC(CC3OC(=O)C)OC4CCC5(C)C(CCC6C5CCC7(C)C(C(O)CC67O)C8=CC(=O)OC8)C4)OC2C MGVYFNHJWXJYBE-UHFFFAOYSA-N 0.000 description 1
229960004977 anhydrous lactose Drugs 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
BLEBFDYUDVZRFG-UHFFFAOYSA-N dichloromethane;propan-2-ol Chemical compound ClCCl.CC(C)O BLEBFDYUDVZRFG-UHFFFAOYSA-N 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
229930182470 glycoside Natural products 0.000 description 1
150000002338 glycosides Chemical class 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
229920003145 methacrylic acid copolymer Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
IQSHMXAZFHORGY-UHFFFAOYSA-N methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O IQSHMXAZFHORGY-UHFFFAOYSA-N 0.000 description 1
-1 methylprocillaridin Chemical compound 0.000 description 1
229960003746 metildigoxin Drugs 0.000 description 1
IYJMSDVSVHDVGT-PEQKVOOWSA-N metildigoxin Chemical compound O1[C@H](C)[C@@H](OC)[C@@H](O)C[C@@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O IYJMSDVSVHDVGT-PEQKVOOWSA-N 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
230000008693 nausea Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000001993 wax Substances 0.000 description 1

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Environmental & Geological Engineering (AREA)
Anesthesiology (AREA)
Vascular Medicine (AREA)
Medicinal Preparation (AREA)
Molecular Biology (AREA)

IE245579A 1978-12-22 1979-12-18 A pharmaceutical preparation comprising a cardiac glycoside in combination with a polymer,and a process for preparation thereof IE48717B1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE7813245A SE426548B (sv)	1978-12-05	1978-12-22	Fast farmaceutisk beredning innehallande en terapeutiskt effektiv hjertglykosid och en polymer

Publications (2)

Publication Number	Publication Date
IE792455L IE792455L (en)	1980-06-22
IE48717B1 true IE48717B1 (en)	1985-05-01

Family

ID=20336688

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IE245579A IE48717B1 (en)	1978-12-22	1979-12-18	A pharmaceutical preparation comprising a cardiac glycoside in combination with a polymer,and a process for preparation thereof

Country Status (7)

Country	Link
DE (1)	DE2966037D1 (de)
ES (1)	ES487182A0 (de)
FI (1)	FI794006A7 (de)
GR (1)	GR74016B (de)
IE (1)	IE48717B1 (de)
NO (1)	NO152634C (de)
PT (1)	PT70618A (de)

1979
- 1979-12-13 DE DE7979850111T patent/DE2966037D1/de not_active Expired
- 1979-12-18 IE IE245579A patent/IE48717B1/en unknown
- 1979-12-20 FI FI794006A patent/FI794006A7/fi not_active Application Discontinuation
- 1979-12-20 PT PT7061879A patent/PT70618A/pt unknown
- 1979-12-21 GR GR60840A patent/GR74016B/el unknown
- 1979-12-21 ES ES487182A patent/ES487182A0/es active Granted
- 1979-12-21 NO NO794251A patent/NO152634C/no unknown

Also Published As

Publication number	Publication date
DE2966037D1 (en)	1983-09-08
PT70618A (en)	1980-01-01
ES8101888A1 (es)	1980-12-16
NO152634C (no)	1985-10-30
ES487182A0 (es)	1980-12-16
FI794006A7 (fi)	1981-01-01
NO794251L (no)	1980-06-24
GR74016B (de)	1984-06-06
NO152634B (no)	1985-07-22
IE792455L (en)	1980-06-22

Publication	Publication Date	Title
EP0013263B1 (de)	1983-08-03	Ein Herzglykosid in Kombination mit einem Polymer enthaltendes pharmazeutisches Präparat und Verfahren zu dessen Herstellung
EP0013262B1 (de)	1983-08-03	Ein Herzglykosid mit einem polymeren Überzug enthaltendes pharmazeutisches Präparat und Verfahren zu dessen Herstellung
US4415547A (en)	1983-11-15	Sustained-release pharmaceutical tablet and process for preparation thereof
EP0385846B1 (de)	1993-02-10	2-Propylvaleriansäure enthaltende Arzneizubereitung mit verzögerter Wirkstofffreigabe
US4427648A (en)	1984-01-24	Dipyridamole-containing pharmaceutical form
US4634587A (en)	1987-01-06	Sustained release quinidine dosage form
DE69529050T2 (de)	2003-10-09	Orale dosierungsformen mit pulverschicht
US4935247A (en)	1990-06-19	Composition for the oral administration of pharmaceuticals
US4806361A (en)	1989-02-21	Medicaments in sustained release unit dose form
PL188834B1 (pl)	2005-04-29	Farmaceutyczne formulacje zawierające tramadol lub jego fizjologicznie akceptowane sole oraz sposóbwytwarzania tych formulacji
JPH0237327B2 (de)	1990-08-23
HUE031603T2 (en)	2017-07-28	Medicinal or food preparation with extended release characteristics and resistance to ethanol
JP2001511443A (ja)	2001-08-14	抗潰瘍活性化合物を含んでなる経口医薬製剤およびその製造方法
CN108066319B (zh)	2022-01-14	一种枸橼酸托法替布肠溶缓释微丸及其制备方法
NO323230B1 (no)	2007-02-05	Mikrogranulater for kontrollert frigjoring for oral administrering som inneholder cisplatin, farmasoytiske preparater derav og anvendelse derav.
DE69327004T2 (de)	2000-06-29	Pharmazeutische formulierungen mit kontrollierter freigabe von 3'-azido-3'-deoxythymidin und verfahren zur verwendung
US12070446B2 (en)	2024-08-27	Standardized psychoactive alkaloid extract composition
JPS61145124A (ja)	1986-07-02	膵臓酵素製品およびその製造方法
AU588258B2 (en)	1989-09-14	Controlled release nifedipine preparation
WO2008083561A1 (en)	2008-07-17	Oral pharmaceutical composition of glycyrrhizin or its salts and the preparation method thereof
DE69816124T2 (de)	2004-05-06	Pharmazeutische zusammensetzungen enthaltend zafirlukast
NO774400L (no)	1978-07-26	Fremgangsmaate til fremstilling av farmasoeytiske sammensetninger
JPH04103525A (ja)	1992-04-06	難水溶性薬物の持続性製剤化方法
EP4313155A1 (de)	2024-02-07	Orale formulierung von ivermectin und verwendungen davon
NZ192442A (en)	1984-05-31	Pharmaceutical preparations: cardiac glycoside in combination with polymer